The order reverses an administrative law judge’s ruling on the deal last fall. Illumina, a DNA sequencing provider, finalized its purchase of Grail in August 2021.
The FTC said the acquisition will decrease innovation in the market for early cancer detection tests and raise prices, since Illuminia is the dominant producer of the genetic sequencing technology used to analyze blood samples from the tests. The decision, which the FTC passed in a 4-0 vote, is the latest sign that the commission is ramping up challenges to anticompetitive corporate behavior.
Illumina told The Wall Street Journal it intends to appeal the FTC’s decision.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.